Prab: CSV import

2024-03-06T00:02:45Z

CSV import

New page

[[File:Fipravirimat.svg|thumb|{{PAGENAME}}]] <br>'''Fipravirimat''' (also known as T-705 or favipiravir) is an [[antiviral drug]] that has been developed and manufactured by [[Toyama Chemical]] of Japan with activity against many RNA viruses. Its antiviral effect is based on the inhibition of [[RNA-dependent RNA polymerase]], an enzyme necessary for the replication of these viruses.

== History ==

Fipravirimat was developed by Toyama Chemical Co., Ltd. in the late 1990s and early 2000s. It was initially developed as a potential treatment for [[Influenza virus|influenza]], but its broad-spectrum antiviral activity was soon recognized.

== Mechanism of Action ==

Fipravirimat is a prodrug that is metabolized into its active form, favipiravir-ribofuranosyl-5'-triphosphate (RTP). This active form mimics the natural substrate of the viral RNA-dependent RNA polymerase, effectively inhibiting the enzyme and halting viral replication.

== Clinical Use ==

Fipravirimat has been used in the treatment of life-threatening infections such as [[Ebola virus disease|Ebola]] and [[Influenza A virus subtype H1N1|H1N1 influenza]]. It is also being studied for use in the treatment of other RNA virus infections, including [[Norovirus]], [[Enterovirus]], and [[Zika virus]].

== Safety and Side Effects ==

The most common side effects of fipravirimat include nausea, diarrhea, and elevated liver enzymes. Serious side effects are rare but can include severe allergic reactions and changes in heart rhythm.

== See Also ==

* [[Antiviral drug]]
* [[RNA-dependent RNA polymerase]]
* [[Ebola virus disease]]
* [[Influenza A virus subtype H1N1]]

[[Category:Antiviral drugs]]
[[Category:Prodrugs]]
[[Category:RNA virus antivirals]]

{{Antiviraldrugs-stub}}

Fipravirimat - Revision history

Prab: CSV import